Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach

Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach Richard M. Stone Oncologist 2004; 9: 259-270 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in acute and chronic leukemias and multiple myeloma and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the rationale for using imatinib as front-line therapy for chronic phase CML. Interpret the results of the phase III trial comparing imatinib with interferon-alfa plus Ara-C in chronic-phase CML. Evaluate various options for CML treatment including imatinib, oral chemotherapy, interferon-based approaches, and allogeneic stem cell transplantation. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 28, 2004 Most Recent Review: Oct. 13, 2005* Most Recent Update: May 28, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.